Global circRNA-LNP Formulation 麻豆原创 Research Report 2024

Publication ID:

PB511243479

Publication Date:

November 12, 2024

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global circRNA-LNP Formulation market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of %during the forecast period 2024-2030.
Circular RNAs (circRNAs) are covalently closed RNA molecules generated mainly from pre-mRNA back-splicing, and have also been found to function as mRNAs to direct protein synthesis inside cells. As a new generation of therapeutic mRNAs, circRNAs may address some of the limitations of linear mRNA including increased stability, reduced immunogenicity, and tissue/cell-specific translation. Therefore, translatable circRNAs are able to produce more therapeutic protein inside the body than conventional mRNA, with the potential to engineer cells, replace damaged proteins, or add new beneficial proteins for patients with serious diseases.LNPs have been proven to be an effective drug delivery system for RNA therapeutics which can be easily degraded in vivo. The lipid layer can fuse with the cell membrane, allowing the encapsulated RNA to enter the cell and exert its therapeutic effect. They also protect therapeutic agents from degradation and improve their bioavailability.
North American market for circRNA-LNP Formulation is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for circRNA-LNP Formulation is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of circRNA-LNP Formulation include Orna Therapeutics, GenScript, Creative Biogene, Catalent, Creative Biolabs, VectorBuilder, Guangzhou Geneseed Biotech. Co., Ltd., Porton Pharma Solutions, Ltd, Recipharm AB, Precigenome LLC, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for circRNA-LNP Formulation, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding circRNA-LNP Formulation.
The circRNA-LNP Formulation market size, estimations, and forecasts are provided in terms of sales volume (Kg) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global circRNA-LNP Formulation market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the circRNA-LNP Formulation manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
麻豆原创 Segmentation
By Company
Orna Therapeutics
GenScript
Creative Biogene
Catalent
Creative Biolabs
VectorBuilder
Guangzhou Geneseed Biotech. Co., Ltd.
Porton Pharma Solutions, Ltd
Recipharm AB
Precigenome LLC
by Type
Premade
Customized
by Application
Scientific Research
Pharmaceuticals
Production by Region
North America
Europe
China
Japan
Consumption by Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of circRNA-LNP Formulation manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of circRNA-LNP Formulation in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 circRNA-LNP Formulation 麻豆原创 Overview
1.1 Product Definition
1.2 circRNA-LNP Formulation by Type
1.2.1 Global circRNA-LNP Formulation 麻豆原创 Value Comparison by Type (2024-2030)
1.2.2 Premade
1.2.3 Customized
1.3 circRNA-LNP Formulation by Application
1.3.1 Global circRNA-LNP Formulation 麻豆原创 Value by Application (2024-2030)
1.3.2 Scientific Research
1.3.3 Pharmaceuticals
1.4 Global circRNA-LNP Formulation 麻豆原创 Size Estimates and Forecasts
1.4.1 Global circRNA-LNP Formulation Revenue 2019-2030
1.4.2 Global circRNA-LNP Formulation Sales 2019-2030
1.4.3 Global circRNA-LNP Formulation 麻豆原创 Average Price (2019-2030)
1.5 Assumptions and Limitations
2 circRNA-LNP Formulation 麻豆原创 Competition by Manufacturers
2.1 Global circRNA-LNP Formulation Sales 麻豆原创 Share by Manufacturers (2019-2024)
2.2 Global circRNA-LNP Formulation Revenue 麻豆原创 Share by Manufacturers (2019-2024)
2.3 Global circRNA-LNP Formulation Average Price by Manufacturers (2019-2024)
2.4 Global Key Players of circRNA-LNP Formulation, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of circRNA-LNP Formulation, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of circRNA-LNP Formulation, Product Type & Application
2.7 Global Key Manufacturers of circRNA-LNP Formulation, Date of Enter into This Industry
2.8 Global circRNA-LNP Formulation 麻豆原创 Competitive Situation and Trends
2.8.1 Global circRNA-LNP Formulation 麻豆原创 Concentration Rate
2.8.2 The Global 5 and 10 Largest circRNA-LNP Formulation Players 麻豆原创 Share by Revenue
2.8.3 Global circRNA-LNP Formulation 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global circRNA-LNP Formulation 麻豆原创 Scenario by Region
3.1 Global circRNA-LNP Formulation 麻豆原创 Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global circRNA-LNP Formulation Sales by Region: 2019-2030
3.2.1 Global circRNA-LNP Formulation Sales by Region: 2019-2024
3.2.2 Global circRNA-LNP Formulation Sales by Region: 2025-2030
3.3 Global circRNA-LNP Formulation Revenue by Region: 2019-2030
3.3.1 Global circRNA-LNP Formulation Revenue by Region: 2019-2024
3.3.2 Global circRNA-LNP Formulation Revenue by Region: 2025-2030
3.4 North America circRNA-LNP Formulation 麻豆原创 Facts & Figures by Country
3.4.1 North America circRNA-LNP Formulation 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America circRNA-LNP Formulation Sales by Country (2019-2030)
3.4.3 North America circRNA-LNP Formulation Revenue by Country (2019-2030)
3.4.4 United States
3.4.5 Canada
3.5 Europe circRNA-LNP Formulation 麻豆原创 Facts & Figures by Country
3.5.1 Europe circRNA-LNP Formulation 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe circRNA-LNP Formulation Sales by Country (2019-2030)
3.5.3 Europe circRNA-LNP Formulation Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific circRNA-LNP Formulation 麻豆原创 Facts & Figures by Region
3.6.1 Asia Pacific circRNA-LNP Formulation 麻豆原创 Size by Region: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific circRNA-LNP Formulation Sales by Region (2019-2030)
3.6.3 Asia Pacific circRNA-LNP Formulation Revenue by Region (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America circRNA-LNP Formulation 麻豆原创 Facts & Figures by Country
3.7.1 Latin America circRNA-LNP Formulation 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America circRNA-LNP Formulation Sales by Country (2019-2030)
3.7.3 Latin America circRNA-LNP Formulation Revenue by Country
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa circRNA-LNP Formulation 麻豆原创 Facts & Figures by Country
3.8.1 Middle East and Africa circRNA-LNP Formulation 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa circRNA-LNP Formulation Sales by Country (2019-2030)
3.8.3 Middle East and Africa circRNA-LNP Formulation Revenue by Country
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global circRNA-LNP Formulation Sales by Type (2019-2030)
4.1.1 Global circRNA-LNP Formulation Sales by Type (2019-2024)
4.1.2 Global circRNA-LNP Formulation Sales by Type (2025-2030)
4.1.3 Global circRNA-LNP Formulation Sales 麻豆原创 Share by Type (2019-2030)
4.2 Global circRNA-LNP Formulation Revenue by Type (2019-2030)
4.2.1 Global circRNA-LNP Formulation Revenue by Type (2019-2024)
4.2.2 Global circRNA-LNP Formulation Revenue by Type (2025-2030)
4.2.3 Global circRNA-LNP Formulation Revenue 麻豆原创 Share by Type (2019-2030)
4.3 Global circRNA-LNP Formulation Price by Type (2019-2030)
5 Segment by Application
5.1 Global circRNA-LNP Formulation Sales by Application (2019-2030)
5.1.1 Global circRNA-LNP Formulation Sales by Application (2019-2024)
5.1.2 Global circRNA-LNP Formulation Sales by Application (2025-2030)
5.1.3 Global circRNA-LNP Formulation Sales 麻豆原创 Share by Application (2019-2030)
5.2 Global circRNA-LNP Formulation Revenue by Application (2019-2030)
5.2.1 Global circRNA-LNP Formulation Revenue by Application (2019-2024)
5.2.2 Global circRNA-LNP Formulation Revenue by Application (2025-2030)
5.2.3 Global circRNA-LNP Formulation Revenue 麻豆原创 Share by Application (2019-2030)
5.3 Global circRNA-LNP Formulation Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Orna Therapeutics
6.1.1 Orna Therapeutics Company Information
6.1.2 Orna Therapeutics Description and Business Overview
6.1.3 Orna Therapeutics circRNA-LNP Formulation Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Orna Therapeutics circRNA-LNP Formulation Product Portfolio
6.1.5 Orna Therapeutics Recent Developments/Updates
6.2 GenScript
6.2.1 GenScript Company Information
6.2.2 GenScript Description and Business Overview
6.2.3 GenScript circRNA-LNP Formulation Sales, Revenue and Gross Margin (2019-2024)
6.2.4 GenScript circRNA-LNP Formulation Product Portfolio
6.2.5 GenScript Recent Developments/Updates
6.3 Creative Biogene
6.3.1 Creative Biogene Company Information
6.3.2 Creative Biogene Description and Business Overview
6.3.3 Creative Biogene circRNA-LNP Formulation Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Creative Biogene circRNA-LNP Formulation Product Portfolio
6.3.5 Creative Biogene Recent Developments/Updates
6.4 Catalent
6.4.1 Catalent Company Information
6.4.2 Catalent Description and Business Overview
6.4.3 Catalent circRNA-LNP Formulation Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Catalent circRNA-LNP Formulation Product Portfolio
6.4.5 Catalent Recent Developments/Updates
6.5 Creative Biolabs
6.5.1 Creative Biolabs Company Information
6.5.2 Creative Biolabs Description and Business Overview
6.5.3 Creative Biolabs circRNA-LNP Formulation Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Creative Biolabs circRNA-LNP Formulation Product Portfolio
6.5.5 Creative Biolabs Recent Developments/Updates
6.6 VectorBuilder
6.6.1 VectorBuilder Company Information
6.6.2 VectorBuilder Description and Business Overview
6.6.3 VectorBuilder circRNA-LNP Formulation Sales, Revenue and Gross Margin (2019-2024)
6.6.4 VectorBuilder circRNA-LNP Formulation Product Portfolio
6.6.5 VectorBuilder Recent Developments/Updates
6.7 Guangzhou Geneseed Biotech. Co., Ltd.
6.7.1 Guangzhou Geneseed Biotech. Co., Ltd. Company Information
6.7.2 Guangzhou Geneseed Biotech. Co., Ltd. Description and Business Overview
6.7.3 Guangzhou Geneseed Biotech. Co., Ltd. circRNA-LNP Formulation Sales, Revenue and Gross Margin (2019-2024)
6.7.4 Guangzhou Geneseed Biotech. Co., Ltd. circRNA-LNP Formulation Product Portfolio
6.7.5 Guangzhou Geneseed Biotech. Co., Ltd. Recent Developments/Updates
6.8 Porton Pharma Solutions, Ltd
6.8.1 Porton Pharma Solutions, Ltd Company Information
6.8.2 Porton Pharma Solutions, Ltd Description and Business Overview
6.8.3 Porton Pharma Solutions, Ltd circRNA-LNP Formulation Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Porton Pharma Solutions, Ltd circRNA-LNP Formulation Product Portfolio
6.8.5 Porton Pharma Solutions, Ltd Recent Developments/Updates
6.9 Recipharm AB
6.9.1 Recipharm AB Company Information
6.9.2 Recipharm AB Description and Business Overview
6.9.3 Recipharm AB circRNA-LNP Formulation Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Recipharm AB circRNA-LNP Formulation Product Portfolio
6.9.5 Recipharm AB Recent Developments/Updates
6.10 Precigenome LLC
6.10.1 Precigenome LLC Company Information
6.10.2 Precigenome LLC Description and Business Overview
6.10.3 Precigenome LLC circRNA-LNP Formulation Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Precigenome LLC circRNA-LNP Formulation Product Portfolio
6.10.5 Precigenome LLC Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 circRNA-LNP Formulation Industry Chain Analysis
7.2 circRNA-LNP Formulation Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 circRNA-LNP Formulation Production Mode & Process
7.4 circRNA-LNP Formulation Sales and 麻豆原创ing
7.4.1 circRNA-LNP Formulation Sales Channels
7.4.2 circRNA-LNP Formulation Distributors
7.5 circRNA-LNP Formulation Customers
8 circRNA-LNP Formulation 麻豆原创 Dynamics
8.1 circRNA-LNP Formulation Industry Trends
8.2 circRNA-LNP Formulation 麻豆原创 Drivers
8.3 circRNA-LNP Formulation 麻豆原创 Challenges
8.4 circRNA-LNP Formulation 麻豆原创 Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 麻豆原创 Size Estimation
10.1.3 麻豆原创 Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

Companies Mentioned:

Orna Therapeutics
GenScript
Creative Biogene
Catalent
Creative Biolabs
VectorBuilder
Guangzhou Geneseed Biotech. Co., Ltd.
Porton Pharma Solutions, Ltd
Recipharm AB
Precigenome LLC

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.